Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | POLA1 | P09884 | 1/20 | 0.67 |
| ▸ | POLD1 | P28340 | 1/20 | 0.67 |
| ▸ | TK1 | P04183 | 5/20 | 0.57 |
| ▸ | DTYMK | P23919 | 4/20 | 0.51 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29309852 | 0.95 | POLB (0.60) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL24556735 | 0.91 | POLB (0.56) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL18844513 | 0.89 | POLB (0.71) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL21579405 | 0.89 | POLB (0.71) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL23934882 | 0.89 | POLB (0.71) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL24370822 | 0.88 | POLB (0.72) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL27102638 | 0.88 | POLB (0.72) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL22074478 | 0.88 | POLB (0.69) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL23635761 | 0.88 | POLB (0.71) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL1332945 | 0.88 | POLB (0.71) | POLBPOLA1POLD1TK1DTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210207192-A1 | NUCLEOTIDE ANALOGS | ABBOTT MOLECULAR INC. | 2021-07-08 | — | — | US | disclosed |
| EP-3842532-A1 | METHOD OF AMPLIFYING MRNAS AND FOR PREPARING FULL LENGTH MRNA LIBRARIES | baseclick GmbH (DE) | 2021-06-30 | — | — | EP | disclosed |
| US-10995363-B2 | Nucleotide analogs | ABBOTT MOLECULAR INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200157606-A1 | NUCLEOTIDE ANALOGS | ABBOTT MOLECULAR INC. | 2020-05-21 | — | — | US | disclosed |
| US-20180127816-A1 | METHODS FOR CHEMICAL LIGATION OF NUCLEIC ACIDS | ILLUMINA, INC. (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995363-B2 | Nucleotide analogs | NUDT1, NT5C3B, RNGTT | POLB 32/4885POLA1 159/4885POLD1 361/4885 |
| US-20200157606-A1 | NUCLEOTIDE ANALOGS | NUDT1, NT5C3B, RNGTT | POLB 32/4885POLA1 159/4885POLD1 361/4885 |
| US-20210207192-A1 | NUCLEOTIDE ANALOGS | NUDT1, NT5C3B, RNGTT | POLB 32/4885POLA1 159/4885POLD1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.